Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$64.11 - $139.13
Next Earnings Date
May 05 2025
Next Earnings Date
May 05 2025
Latest price
Market Cap | $5.08B |
EV | $4.96B |
Shares Outstanding | 53.46M |
Beta | 0.88 |
Analyst Rating | BUY |
Analyst Target Price | $177.35 |
P/E 2025E | - |
P/Revenue 2025E | 8.24x |
Revenue | - |
EPS | -20.00% |
Operating Cash Flow | -5.90% |
Free Cash Flow | -5.80% |
Revenue | 57.90% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 90.80% |
Net Profit Margin 2025E | -25.73% |
ROE 2025E | -42.32% |
ROCE 2024 | -231.63% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Axsome Therapeutics, Inc.
AXSM
Sector
Healthcare
Industry
Biotechnology
CEO
Tabuteau, Herriot
Employees
683
Website
www.axsome.comIPO Date
2015-11-19
Headquarters
One World Trade Center, 22nd Floor, New York, New York, 10007, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved